InMed Pharmaceuticals (INM) Research Hub

InMed Pharmaceuticals (INM) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.59 USD (+10.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.00, market cap 0.00B. This hub links to the full technical, earnings and options research available for INM.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, CA
Last close1.59 USD (+10.42%)
52-week range1.25 USD – 2.33 USD
Trend regimeRange
14-day RSI76.5 (Overbought)
Trailing P/E-0.00
Market cap0.00B
Dividend yield0.00%
Next earnings2026-09-18

Available research for INM

Earnings

INM earnings date and last-quarter result: next report 2026-09-18, P/E -0.00. Updated 2026-07-23.

Options: Covered Call

Covered Call on INM: how it works, illustrative setup around the real 1.59 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on INM: how it works, illustrative setup around the real 1.59 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on INM: how it works, illustrative setup around the real 1.59 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

INM technical analysis: range, last 1.59 USD, RSI 76.5, 52w range 1.25 USD–2.33 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is INM in?

InMed Pharmaceuticals (INM) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.

Is INM in an uptrend or downtrend?

As of 2026-10-26, INM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is INM's trailing P/E ratio?

INM's trailing P/E is -0.00, with a market cap of 0.00B. See the earnings research page for full valuation detail.

When does INM next report earnings?

INM is next scheduled to report earnings on 2026-09-18.